Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Palisade Bio, Inc. (PALI)

2.24   0.02 (0.9%) 01-27 16:00
Open: 2.17 Pre. Close: 2.22
High: 2.245 Low: 2.11
Volume: 368,434 Market Cap: 5(M)

Technical analysis

as of: 2023-01-27 4:46:56 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 6.94     One year: 9.97
Support: Support1: 1.74    Support2: 1.44
Resistance: Resistance1: 5.94    Resistance2: 8.53
Pivot: 2.54
Moving Average: MA(5): 2.33     MA(20): 2.88
MA(100): 4.17     MA(250): 20.63
MACD: MACD(12,26): -0.3     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 6.4     %D(3): 5.4
RSI: RSI(14): 42.1
52-week: High: 76.5  Low: 0.44
Average Vol(K): 3-Month: 3,497 (K)  10-Days: 455 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PALI ] has closed above bottom band by 11.8%. Bollinger Bands are 68.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.25 - 2.26 2.26 - 2.27
Low: 2.08 - 2.1 2.1 - 2.11
Close: 2.22 - 2.24 2.24 - 2.26

Company Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Headline News

Sat, 28 Jan 2023
Pali Medical College gets Centre’s nod for PG courses - Times of India

Sat, 28 Jan 2023
Palisade Bio Inc. (NASDAQ:PALI) Rises 59.40% In 2023; Is It Still ... - Marketing Sentinel

Fri, 27 Jan 2023
Here is why Palisade Bio Inc. (PALI) stock volatility recorded over ... - Invest Chronicle

Wed, 25 Jan 2023
Hacked road sign along Pali Highway tied to deadly protests in GA - Hawaii News Now

Mon, 23 Jan 2023
Premarket Mover: Palisade Bio Inc (PALI) Up 1.68% - InvestorsObserver

Tue, 17 Jan 2023
Palisade Bio Inc (PALI) Down 2.62% in Premarket Trading - InvestorsObserver

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 2 (M)
Shares Float 1 (M)
% Held by Insiders 11.4 (%)
% Held by Institutions 11 (%)
Shares Short 98 (K)
Shares Short P.Month 3 (K)

Stock Financials

EPS 11.44
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 8.06
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -58
Return on Equity (ttm) -115.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -7.48
Qtrly Earnings Growth 0
Operating Cash Flow -13 (M)
Levered Free Cash Flow -6 (M)

Stock Valuations

PE Ratio 0.19
PEG Ratio 0
Price to Book value 0.27
Price to Sales 0
Price to Cash Flow -0.35

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-07-17
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.